Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypochlorous Acid SCHEMBL6429296 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2KIF11MMECA1CA2 | |
| SCHEMBL186262 | 0.95 | — | — | |
| SCHEMBL159223 | 0.95 | — | — | |
| SCHEMBL47274 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL74754 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL1337777 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL159222 | 0.93 | — | — | |
| SCHEMBL2236696 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL5276199 | 0.93 | SMN1; SMN2 (0.39) | SMN1; SMN2KIF11MMECA1CA2 | |
| Hydrochloric Acid SCHEMBL159221 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351131-B2 | Anti-inflammatory composition | NEOPHARM CO., LTD. (KR) | 2022-06-07 | — | — | US | disclosed |
| US-20190247344-A1 | ANTI-INFLAMMATORY COMPOSITION | NEOPHARM CO., LTD. (KR) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351131-B2 | Anti-inflammatory composition | TNF, CUTA, CD68 | SMN1; SMN2 3847/4885KIF11 4713/4885MME 3445/4885 |
| US-20190247344-A1 | ANTI-INFLAMMATORY COMPOSITION | TNF, CUTA, CD68 | SMN1; SMN2 3847/4885KIF11 4713/4885MME 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.